The price of menstrual products is skyrocketing from inflation, tariffs

Average price of menstrual products rose ~40% since 2020 (from $5.37 to $7.43 per unit) while dollar sales grew ~30% and unit sales have fallen ~6% since 2022, signaling price-driven demand shifts. Tariff-related costs have risen materially — U.S. cotton-containing menstrual product tariffs generated $115M in 2025 vs $42M in 2020 — and major consumer-packaged-goods firms reported tariff impacts (P&G cited ~$1B annual tariff impact; Kimberly‑Clark ~$300M gross tariff costs). CPI context: overall CPI +2.4% year-over-year (Feb) and personal care products +22.1% vs Jan 2020; companies are reallocating portfolios (e.g., Edgewell sold feminine care for $340M) and consumers are trading down or shifting to reusables for affordability.

Analysis

The core dynamic is not merely headline price inflation but a structural margin squeeze amplified by persistent demand elasticity: consumers are trading down to private-label, extending product lifespans with reusables, or abandoning purchases — a change that reduces long-run category stickiness and weakens the annuity-like revenue profile incumbents have relied on. For large brand owners this means higher input and tariff-driven costs cannot be fully passed through without accelerating share loss to smaller, nimbler competitors and retailer brands.

Second-order winners are firms that control distribution or can scale low-cost manufacturing and product innovation quickly — retailers with private-label programs and contract manufacturers that enable reusables or lower-cost SKUs. Conversely, legacy branded players face compounded risk: elevated gross-cost shocks plus the erosion of lifetime customer relationships, which raises the odds of strategic portfolio pruning or fire-sale divestitures over the next 12–36 months.

Regulatory and policy catalysts could materially shift the setup. Tariff rollbacks, reclassification of products for tax exemption, or subsidized domestic capacity would relieve cost pressure and reverse some volume trends, but those outcomes are multi-quarter to multi-year probabilities. Near-term monitoring points: quarterly tariff disclosures, private-label SKU velocity at national chains, and early revenue/traffic signals from reusable-focused entrants.

Key Decisions for Investors

• Pair trade (6–12 month): short PG (core branded exposure) vs long FLEX (contract manufacturing/outsourcing beneficiary). Size 1:1 notional; target 20–30% asymmetric payoff if branded margins compress and manufacturing outsourcers win share. Use puts on PG (3–6 month) and outright stock or call spread on FLEX to limit downside.
• Long CVS (3–9 month tactical): overweight private-label retail exposure via small position (3–5% book). Implement via long stock or buy-call spread to capture upside from faster private-label adoption while capping premium decay. Set stop at 10% trailing loss.
• Short KMB (9–18 month): tactical short targeting multiple quarters of margin pressure and slower top-line growth; use 6–12 month puts to limit capital outlay. Risk: successful cost-pass or divestiture execution could produce sharp rebounds—size accordingly and hedge with a small long PG call if you want cross-coverage.
• Event-driven play (12–24 month): screen for mid-cap feminine-care assets or startups that could be acquisition targets; establish a small long basket of high-share reusable/organic brands (private or public where available) to capture M&A re-rating if incumbents accelerate portfolio sales. Exit on acquisition or 30% profit.